Index DJIA, S&P 500
P/E 29.47
EPS (ttm) 5.24
Insider Own 0.17%
Shs Outstand 2.61B
Perf Week -2.50%
Market Cap 371.73B
Forward P/E 14.37
EPS next Y 10.75
Insider Trans -1.14%
Shs Float 2.40B
Perf Month 2.71%
Income 13.64B
PEG 5.67
EPS next Q 2.37
Inst Own 70.79%
Short Float / Ratio 0.55% / 1.95
Perf Quarter -5.07%
Sales 95.35B
P/S 3.90
EPS this Y -1.31%
Inst Trans -0.39%
Short Interest 13.19M
Perf Half Y -3.49%
Book/sh 29.59
P/B 5.22
EPS next Y 7.28%
ROA 7.56%
Target Price 175.84
Perf Year -12.84%
Cash/sh 9.77
P/C 15.81
EPS next 5Y 5.20%
ROE 17.70%
52W Range 144.95 - 181.04
Perf YTD -12.58%
Dividend 4.60
P/FCF 23.62
EPS past 5Y 70.31%
ROI 14.02%
52W High -14.70%
Beta 0.53
Dividend % 2.98%
Quick Ratio 0.96
Sales past 5Y 4.55%
Gross Margin 68.02%
52W Low 6.53%
ATR 2.06
Employees 152700
Current Ratio 1.21
Sales Q/Q -10.36%
Oper. Margin 26.68%
RSI (14) 53.41
Volatility 1.26% 1.32%
Optionable Yes
Debt/Eq 0.42
EPS Q/Q 18.10%
Profit Margin 14.31%
Rel Volume 0.91
Prev Close 155.40
Shortable Yes
LT Debt/Eq 0.37
Earnings Oct 17 BMO
Payout 66.07%
Avg Volume 6.78M
Price 154.42
Recom 2.17
SMA20 1.58%
SMA50 1.07%
SMA200 -3.10%
Volume 6,146,037
Change -0.63%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-01-23 Upgrade
UBS
Neutral → Buy
$167 → $180
Oct-05-23 Initiated
RBC Capital Mkts
Outperform
$178
Sep-06-23 Initiated
HSBC Securities
Hold
$175
May-30-23 Resumed
Citigroup
Buy
$185
Mar-29-23 Initiated
UBS
Neutral
$164
Mar-01-23 Initiated
Guggenheim
Neutral
$161
Nov-18-22 Initiated
Credit Suisse
Neutral
$170
Oct-18-22 Initiated
Barclays
Equal Weight
$175
Oct-14-22 Reiterated
BofA Securities
Neutral
$185 → $178
Jun-22-22 Initiated
Daiwa Securities
Outperform
May-23-22 Resumed
SVB Leerink
Outperform
$200
Apr-06-22 Resumed
Morgan Stanley
Equal-Weight
$173
Mar-16-22 Downgrade
Bernstein
Outperform → Mkt Perform
$180 → $183
Mar-02-22 Resumed
BofA Securities
Neutral
$185
Dec-17-21 Initiated
Goldman
Neutral
$161
Dec-15-21 Reiterated
Citigroup
Buy
$192 → $195
Sep-07-21 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$187
May-28-21 Resumed
Morgan Stanley
Overweight
$187
Apr-28-20 Downgrade
UBS
Buy → Neutral
$163 → $160
Apr-22-20 Upgrade
BofA/Merrill
Neutral → Buy
$150 → $175
Show Previous Ratings
Today 01:05PM
11:35AM
Dec-09-23 05:51AM
Dec-07-23 04:15PM
12:47PM
11:50AM
Loading…
11:50AM
11:20AM
08:52AM
Dec-06-23 12:35PM
11:29AM
09:19AM
08:58AM
06:59AM
05:55AM
01:21AM
06:23PM
Loading…
Dec-05-23 06:23PM
05:45PM
12:03PM
11:12AM
08:07AM
07:57AM
(The Wall Street Journal)
07:40AM
07:18AM
07:17AM
07:15AM
06:01AM
Dec-04-23 05:30AM
(The Wall Street Journal)
Dec-03-23 08:00AM
08:00AM
07:00AM
05:30AM
Loading…
05:30AM
Dec-02-23 02:05PM
06:14AM
Dec-01-23 12:33PM
09:32AM
Nov-30-23 05:16PM
04:30PM
11:04AM
08:40AM
07:21AM
05:30AM
(The Wall Street Journal)
02:13AM
Nov-29-23 06:04PM
05:45PM
05:18PM
09:00AM
05:00AM
Nov-28-23 01:34PM
01:34PM
06:30AM
05:41AM
Nov-27-23 09:56AM
06:03AM
05:30AM
Nov-26-23 07:15AM
06:51AM
06:30AM
05:56AM
Nov-25-23 04:22PM
Nov-24-23 08:20AM
03:49AM
12:07AM
(Associated Press Finance)
Nov-23-23 05:11PM
Nov-22-23 01:01PM
05:06AM
Nov-21-23 03:20PM
12:41PM
11:53AM
08:32AM
Nov-20-23 01:25PM
12:02PM
07:15AM
06:52AM
05:56AM
05:04AM
Nov-19-23 02:05PM
Nov-17-23 09:21AM
06:03AM
Nov-16-23 06:30PM
12:13PM
11:30AM
07:30AM
05:50AM
Nov-15-23 04:31PM
11:57AM
10:07AM
09:57AM
09:00AM
Nov-14-23 05:30AM
Nov-13-23 04:05PM
02:14PM
06:02AM
Nov-11-23 05:00AM
Nov-10-23 07:48AM
07:38AM
Nov-09-23 05:21AM
04:06AM
Nov-08-23 02:53PM
09:45AM
Nov-07-23 09:21AM
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women's Health and Wound Care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The MedTech segment offers products used in the interventional solutions. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Hait William See Remarks Jul 26 Option Exercise 90.44 14,698 1,329,287 102,445 Jul 27 05:52 PM Hait William See Remarks Jul 26 Sale 172.00 14,698 2,528,056 87,747 Jul 27 05:52 PM Fasolo Peter Exec VP, Chief HR Officer Jul 25 Sale 170.32 20,000 3,406,498 102,696 Jul 27 05:52 PM Wengel Kathryn E EVP, Chief TO and Risk Officer Jun 12 Sale 160.00 12,465 1,994,400 65,934 Jun 14 04:19 PM Swanson James D. See Remarks Mar 06 Sale 154.66 1,062 164,199 9,215 Mar 08 04:16 PM McEvoy Ashley EVP, WW Chair, MedTech Feb 10 Option Exercise 0.00 2,999 0 44,812 Feb 14 04:36 PM Taubert Jennifer L EVP, WW Chair, Pharmaceuticals Feb 10 Option Exercise 0.00 3,570 0 130,026 Feb 14 04:36 PM Duato Joaquin CEO and Chairman of the Board Feb 10 Option Exercise 0.00 5,220 0 300,940 Feb 14 04:37 PM Fasolo Peter Exec VP, Chief HR Officer Feb 10 Option Exercise 0.00 2,078 0 116,754 Feb 14 04:35 PM Mongon Thibaut Exec VP, WW Chair, Cons Health Feb 10 Option Exercise 0.00 2,285 0 59,461 Feb 14 04:35 PM Hait William See Remarks Feb 10 Option Exercise 0.00 3,856 0 84,092 Feb 14 04:35 PM Wolk Joseph J Exec VP, CFO Feb 10 Option Exercise 0.00 3,449 0 39,261 Feb 14 04:36 PM Wengel Kathryn E EVP, Chief TO and Risk Officer Feb 10 Option Exercise 0.00 1,807 0 73,118 Feb 14 04:37 PM Swanson James D. See Remarks Feb 10 Option Exercise 0.00 1,291 0 8,355 Feb 14 04:34 PM Broadhurst Vanessa EVP, Global Corp Affairs Feb 10 Option Exercise 0.00 1,592 0 17,259 Feb 14 04:35 PM Decker Robert J VP Corporate Controller Feb 10 Option Exercise 0.00 581 0 16,054 Feb 14 04:35 PM Gorsky Alex Director Jan 17 Option Exercise 72.54 547,692 39,729,578 1,133,194 Jan 18 04:39 PM Duato Joaquin CEO and Chairman of the Board Jan 17 Option Exercise 72.54 148,538 10,774,947 394,515 Jan 18 04:39 PM Wolk Joseph J Exec VP, CFO Dec 13 Option Exercise 88.19 14,781 1,303,589 50,593 Dec 15 04:34 PM Wolk Joseph J Exec VP, CFO Dec 13 Sale 179.60 14,781 2,654,661 35,812 Dec 15 04:34 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite